Eligible patients were randomly allocated in a 1:1:1:1 ratio with a centralised , interactive online system to receive either dose-dense chemotherapy ( administered intravenously every 2 weeks with pegfilgrastim support ) with fluorouracil plus EC-P ( FEC-P ) or EC-P or to receive standard-interval chemotherapy ( administered intravenously every 3 weeks ) with FEC-P or EC-P .